11
20
9
↑11
↓20
—9
Evidence suggests Magnesium maydecreaseMortality.
28 studies (40 claims)
Emerging evidence
Typical effective dose 1000 (1000–1000) mgacross 1 dosed study
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| magnesium plus nimodipine | No effect - no significant differences were found in | mortality | Human | patients with SAH | Not specified | Magnesium as an adjunct to nimodipine in subarachnoid hemorrhage: a meta-analysis. |
| intravenous magnesium | No effect - failed to show any advantage | mortality | Human | patients with acute myocardial infarction (AMI) | Not specified | Magnesium and cardiovascular system.cited 86× |
| magnesium intake | No effect - mediated by | mortality | Human | HFpEF patients | Not specified | Propensity score matched cohort study on magnesium supplementation and mortality in critically ill patients with HFpEF. |
| magnesium treatment | Decreases - improved | ICU mortality rates | Human | HFpEF patients | Not specified | Propensity score matched cohort study on magnesium supplementation and mortality in critically ill patients with HFpEF. |
| magnesium treatment | Decreases - improved | one-year mortality rates | Human | HFpEF patients | Not specified | Propensity score matched cohort study on magnesium supplementation and mortality in critically ill patients with HFpEF. |
| magnesium supplementation (including magnesium sulfate and magnesium oxide) | Decreases - significantly contributed to a decrease | 28-day all-cause mortality rate | Human | older patients | Not specified | Propensity score matched cohort study on magnesium supplementation and mortality in critically ill patients with HFpEF. |
| magnesium supplementation (including magnesium sulfate and magnesium oxide) | Decreases - significantly contributed to a decrease | 28-day all-cause mortality rate | Human | females | Not specified | Propensity score matched cohort study on magnesium supplementation and mortality in critically ill patients with HFpEF. |
| magnesium supplementation (including magnesium sulfate and magnesium oxide) | Decreases - significantly contributed to a decrease | 28-day all-cause mortality rate | Human | those with hypertension | Not specified | Propensity score matched cohort study on magnesium supplementation and mortality in critically ill patients with HFpEF. |
| magnesium supplementation (including magnesium sulfate and magnesium oxide) | Decreases - significantly contributed to a decrease | 28-day all-cause mortality rate | Human | those without diabetes | Not specified | Propensity score matched cohort study on magnesium supplementation and mortality in critically ill patients with HFpEF. |
| magnesium supplementation (including magnesium sulfate and magnesium oxide) | Decreases - significantly contributed to a decrease | 28-day all-cause mortality rate | Human | HFpEF patients | Not specified | Propensity score matched cohort study on magnesium supplementation and mortality in critically ill patients with HFpEF. |
| serum magnesium concentration | Decreases - negative correlation | cardiovascular mortality | Human | — | Not specified. | Relationship of dietary magnesium intake and serum magnesium with hypertension: a review.cited 10× |
| oral magnesium supplementation | No effect - associated with no significant difference | perinatal mortality (stillbirth and neonatal death prior to discharge) | Human | infants | Varied by trial: magnesium oxide (1000 mg daily), magnesium citrate (340-365 mg daily), magnesium gluconate (2-4 g daily), magnesium aspartate (15 mmol or 365 mg daily), and magnesium stearate (128 mg elemental magnesium daily). | Magnesium supplementation in pregnancy.cited 90× |
| Magnesium sulfate infusion in addition to bicarbonate treatment | Decreases - reduced | mortality rate | Human | patients with TCA intoxication | Not specified | Tricyclic antidepressant poisoning treated by magnesium sulfate: a randomized, clinical trial.cited 6× |
| high serum magnesium levels | Decreases - alleviated | cardiovascular mortality risk associated with hyperphosphatemia | HumanMolecular | — | Not specified | Effects of Magnesium on the Phosphate Toxicity in Chronic Kidney Disease: Time for Intervention Studies.cited 31× |
| lower serum magnesium level | Increases - significant risk for | cardiovascular mortality | HumanMolecular | patients receiving dialysis | Not specified | Effects of Magnesium on the Phosphate Toxicity in Chronic Kidney Disease: Time for Intervention Studies.cited 31× |
| magnesium supplementation | Decreases - relative risk (RR) for mortality was 0.54, 95% confidence interval (CI) 0.30-0.96 compared to no supplementation | mortality | Human | adult ICU patients | Not available | Effects of magnesium, phosphate, or zinc supplementation in intensive care unit patients-A systematic review and meta-analysis.cited 7× |
| magnesium supplementation | No effect - not significantly different | sepsis-related mortality | Human | critically ill patients with severe sepsis | — | Effect of magnesium supplementation on lactate clearance in critically ill patients with severe sepsis: a randomized clinical trial.cited 18× |
| serum magnesium levels | No effect - associations with | mortality | Human | patients with CKD | Not available | Magnesium and cardiovascular complications of chronic kidney disease.cited 50× |
| low magnesium intake | Increases - have been associated with a higher | mortality | Human | general population | Not specified | Hypomagnesaemia in kidney transplantation.cited 31× |
| low serum magnesium (SMg) | Increases - has been linked to increased | mortality | Human | general population | Not specified (study analyzed serum magnesium levels, not supplementation). | Association of serum magnesium with all-cause mortality in patients with and without chronic kidney disease in the Dallas Heart Study.cited 30× |
| low magnesium status | Increases - associated with | cardiac mortality | Human | — | Not specified | The Role of Dietary Magnesium in Cardiovascular Disease.cited 2× |
| magnesium sulfate therapy | Decreases - showed significant improvements | short-term mortality and morbidities | Human | neonates with encephalopathy in middle-income countries | Not available | Post-Asphyxial Aftercare and Management of Neonates in Low- and Middle-Income Countries: A Systematic Evidence Synthesis.cited 1× |
| addition of phosphate to existing potassium and magnesium supplements | Decreases - addition of | mortality | Human | those at risk of the refeeding syndrome | — | Inpatient management of severe malnutrition: time for a change in protocol and practice.cited 20× |
| intravenous bolus of 1.5 g of magnesium sulphate followed by an infusion of 12 g of the same salt in 24 h | No effect - No significant differences were found | ICU or hospital mortality | Human | patients undergoing elective cardiac surgery with cardiopulmonary bypass | Intravenous bolus of 1.5 g magnesium sulphate followed by 12 g infusion over 24 hours. | Does post-cardiac surgery magnesium supplementation improve outcome?cited 5× |
| dietary supplementation of magnesium | Decreases - reduces | vascular calcifications and mortality | HumanMolecular | animal models of uremia | Not specified | Magnesium Replacement to Protect Cardiovascular and Kidney Damage? Lack of Prospective Clinical Trials.cited 19× |
| magnesium replacement | Decreases - reduce | vascular damage and mortality | HumanMolecular | uremic population | Not specified | Magnesium Replacement to Protect Cardiovascular and Kidney Damage? Lack of Prospective Clinical Trials.cited 19× |
| Magnesium (Mg) | Decreases - reduces | risk of mortality | Human | human participants | Not mentioned. | Antioxidant/anti-inflammatory effect of Mgcited 12× |
| magnesium | Decreases - had beneficial effects | short-term mortality | Human | adults with sepsis | Not specified | Efficacy of dietary supplements on mortality and clinical outcomes in adults with sepsis and septic shock: A systematic review and network meta-analysis.cited 1× |
| magnesium | Increases - associated with increased risk | total mortality | Human | 38,772 older women in the Iowa Women's Health Study | Not specified | Dietary supplements and mortality rate in older women: the Iowa Women's Health Study.cited 219× |
| higher magnesium depletion score (MDS) | Increases - was associated with increased | all-cause mortality | Human | participants with MASLD or MetALD | Not specified | Magnesium Depletion Score and Mortality in Individuals with Metabolic Dysfunction Associated Steatotic Liver Disease over a Median Follow-Up of 26 Years. |
| higher magnesium depletion score (MDS) | Increases - association became stronger | all-cause mortality | Human | participants who did not meet the estimated average requirement level of Mg intake | Not specified | Magnesium Depletion Score and Mortality in Individuals with Metabolic Dysfunction Associated Steatotic Liver Disease over a Median Follow-Up of 26 Years. |
| higher magnesium depletion score (MDS) | Increases - association became stronger | all-cause mortality | Human | participants with a Fibrosis-4 index (FIB-4) < 1.3 | Not specified | Magnesium Depletion Score and Mortality in Individuals with Metabolic Dysfunction Associated Steatotic Liver Disease over a Median Follow-Up of 26 Years. |
| higher magnesium depletion score (MDS) | Increases - was associated with increased | CVD mortality | Human | participants with MASLD or MetALD | Not specified | Magnesium Depletion Score and Mortality in Individuals with Metabolic Dysfunction Associated Steatotic Liver Disease over a Median Follow-Up of 26 Years. |
| erythropoietin magnesium sulfate | No effect - not statistically significant | mortality | Human | neonates with hypoxic-ischemic encephalopathy | Not specified | Comparison of Different Adjuvant Therapies for Hypothermia in Neonates with Hypoxic-Ischemic Encephalopathy: A Systematic Review and Network Meta-Analysis.cited 2× |
| magnesium sulphate | No effect - no events of mortality or adverse effects | mortality or adverse effects | Human | children up to two years old with acute bronchiolitis | — | Magnesium sulphate for treating acute bronchiolitis in children up to two years of age.cited 10× |
| magnesium sulphate, with or without salbutamol | No effect - no events of mortality or adverse effects | mortality or adverse effects | Human | children up to two years old with acute bronchiolitis | — | Magnesium sulphate for treating acute bronchiolitis in children up to two years of age.cited 10× |
| Magnesium sulphate (MgS04) | Decreases - effective | mortality reduction from eclampsia | Human | women with eclampsia | Not specified | Quantifying the fall in mortality associated with interventions related to hypertensive diseases of pregnancy.cited 44× |
| Magnesium sulphate (MgS04) | Decreases - effective | mortality reduction from pre-eclampsia | Human | women with pre-eclampsia | Not specified | Quantifying the fall in mortality associated with interventions related to hypertensive diseases of pregnancy.cited 44× |
| magnesium sulphate | Decreases - insignificant decrease | stillbirth and perinatal mortality | Human | — | Not specified | Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths.cited 30× |
| magnesium-supplemented cardioplegia | No effect - similar | in-hospital mortality | Human | patients | Not specified | Does magnesium-supplemented cardioplegia reduce cardiac injury? A meta-analysis of randomized controlled trials.cited 8× |
| retention of magnesium-based laxative in the gut | Increases - serves as a reservoir for continuous magnesium absorption and contributes to | mortality | Human | patients with constipation | Not specified (regular use of magnesium-containing laxatives). | Fatal Hypermagnesemia Due to Laxative Use.cited 24× |